FDA unlikely to rule on Merck’s COVID pill before December

FDA unlikely to rule on Merck's COVID pill before December WASHINGTON (AP) — The Food and Drug Administration said Thursday it will ask its outside experts to meet in late November to scrutinize Merck's pill to treat COVID-19. The Nov. 30 meeting means U.S. AP NEWS

WASHINGTON (AP) — The Food and Drug Administration said Thursday it will ask its outside experts to meet in late November to scrutinize Merck’s pill to treat COVID-19.

The Nov. 30 meeting means U.S. regulators almost certainly won’t issue a decision on the drug until December, signaling that the agency will conduct a detailed review of the experimental treatment’s safety and effectiveness. The panelists are likely to vote on whether Merck’s drug should be approved, though the FDA is not required to follow their advice....